CN114807228A - Expression system of T7RNA polymerase and T7 promoter and method for expressing protein in eukaryote by using same - Google Patents
Expression system of T7RNA polymerase and T7 promoter and method for expressing protein in eukaryote by using same Download PDFInfo
- Publication number
- CN114807228A CN114807228A CN202210513779.1A CN202210513779A CN114807228A CN 114807228 A CN114807228 A CN 114807228A CN 202210513779 A CN202210513779 A CN 202210513779A CN 114807228 A CN114807228 A CN 114807228A
- Authority
- CN
- China
- Prior art keywords
- protein
- t7rnap
- expression system
- rev
- t7rna polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 89
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 65
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 42
- 101710137500 T7 RNA polymerase Proteins 0.000 title claims abstract description 28
- 241000206602 Eukaryota Species 0.000 title claims abstract description 15
- 230000001105 regulatory effect Effects 0.000 claims abstract description 10
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 8
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract 3
- 239000012634 fragment Substances 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 25
- 108010048367 enhanced green fluorescent protein Proteins 0.000 claims description 19
- 230000030648 nucleus localization Effects 0.000 claims description 18
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims description 14
- 241000713666 Lentivirus Species 0.000 claims description 13
- 238000004806 packaging method and process Methods 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 4
- 108700043045 nanoluc Proteins 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 101100011365 Caenorhabditis elegans egl-13 gene Proteins 0.000 claims description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 2
- 102000002488 Nucleoplasmin Human genes 0.000 claims description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108060005597 nucleoplasmin Proteins 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 abstract description 27
- 210000000805 cytoplasm Anatomy 0.000 abstract description 21
- 210000000633 nuclear envelope Anatomy 0.000 abstract description 14
- 210000004027 cell Anatomy 0.000 description 77
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 43
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 43
- 239000013612 plasmid Substances 0.000 description 39
- 238000010276 construction Methods 0.000 description 36
- 108020004414 DNA Proteins 0.000 description 27
- 210000004940 nucleus Anatomy 0.000 description 15
- 108700004025 env Genes Proteins 0.000 description 13
- 238000010586 diagram Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 101710150344 Protein Rev Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- 108700026222 vpu Genes Proteins 0.000 description 9
- 101150090490 vpu gene Proteins 0.000 description 9
- 230000035699 permeability Effects 0.000 description 8
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 108700008625 Reporter Genes Proteins 0.000 description 7
- 230000029918 bioluminescence Effects 0.000 description 7
- 238000005415 bioluminescence Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 238000010367 cloning Methods 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000009630 liquid culture Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 5
- 241000793189 Saccharomyces cerevisiae BY4741 Species 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 210000003855 cell nucleus Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 4
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 229950010131 puromycin Drugs 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108091036407 Polyadenylation Proteins 0.000 description 2
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000007222 ypd medium Substances 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 102000017033 Porins Human genes 0.000 description 1
- 108010039259 RNA Splicing Factors Proteins 0.000 description 1
- 102000015097 RNA Splicing Factors Human genes 0.000 description 1
- 101100232295 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GLK1 gene Proteins 0.000 description 1
- 244000253911 Saccharomyces fragilis Species 0.000 description 1
- 235000018368 Saccharomyces fragilis Nutrition 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 108010063039 endodeoxyribonuclease SfiI Proteins 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 102000045429 human PGK1 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940031154 kluyveromyces marxianus Drugs 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 101150098213 rev gene Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07006—DNA-directed RNA polymerase (2.7.7.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present application relates to an expression system of T7RNA polymerase and T7 promoter and a method for expressing protein in eukaryote using the same. The expression system described herein, which comprises Vpu protein and/or Rev-RRE regulatory elements in HIV-1 retrovirus, allows mRNA transcribed by T7 without 5' cap structure to be transported across nuclear membrane to cytoplasm in eukaryotic cells, thereby achieving continuous, stable and efficient expression of foreign proteins.
Description
The present application is a divisional application of the original application with application number 202010343730.7, filed on year 2020, 4/27, entitled "expression system of T7RNA polymerase and T7 promoter and method for expressing protein in eukaryote using the same".
Technical Field
The present application relates to an HIV-1Vpu and Rev-RRE element based T7RNA polymerase (T7 RNAP) and T7 promoter expression system which can be used for sustained, stable and efficient protein expression in eukaryotic cells.
Background
The T7 expression system has been widely used for expression of proteins, and among them, the application in prokaryotes is most common (see, patent document 1). The most typical representative is the pET series plasmid developed by Novagen, which has been widely used for efficient protein expression in E.coli.
In the case of eukaryotes, researchers have conducted studies on the T7 expression system using yeast strains, but have not obtained positive results, and only expression of T7RNAP was detected, and synthesis of target protein under the control of the T7 promoter was not detected (see, non-patent documents 1 and 2).
Researchers have also constructed T7 expression systems in mammalian cells using viruses (e.g., vaccinia virus) as vectors, which are found in the cytoplasm and lost as cells divide; at the same time, the large number of replicated vaccinia viruses will eventually kill the host cells as well. Therefore, the T7 expression system can achieve only transient expression of the protein in the cytoplasm, and it is difficult to achieve sustained and stable expression of the target protein (see non-patent documents 1 and 3).
In order to achieve the continuous and stable expression of proteins in eukaryotic cells, the key point is that eukaryotic mRNA which is processed after transcription in the nucleus is successfully transported to cytoplasm through the nuclear membrane, and then the translation of mRNA into proteins in cytoplasm can be realized. However, since mRNA transcribed from T7RNAP in the nucleus has no 5 'cap structure and 3' poly (A) tail, and cannot be transported out of the nucleus, it affects the translation synthesis of proteins in the cytoplasm, and thus proteins cannot be expressed efficiently.
For the mRNA lacking the 5' cap structure transcribed by T7RNAP, it was found that translation of a protein from a eukaryotic mRNA lacking the 5' cap structure can be facilitated by utilizing an IRES structure in the cytoplasm (see, non-patent document 4), but this study does not address the problem of transport of the mRNA lacking the 5' cap structure transcribed by T7RNAP in the nucleus to the cytoplasm. Also, it has been shown that the addition of a eukaryotic terminator sequence to a transcription unit initiated by the T7 promoter can help the T7RNAP transcript to produce a 3 'poly (A) tail (see, non-patent document 5), but this study does not solve the problem of how to transport mRNA lacking a 5' cap structure from the nucleus to the cytoplasm.
Prior art documents:
patent document 1: CN102643851A
Non-patent document 1: (iii) ELROY-STEIN O, FUERST T R, MOSS B. Cap-induced transformation of mRNA conjugated by alphalobar microorganisms 5' sequence improvements of the performance of the vaccinia virus/bacterial T7hybrid expression system [ J ]. Proceedings of the National Academy of Sciences,1989,86(16):6126-30.
Non-patent document 2: benton B M, Eng W-K, Dunn J, et al, Signal-mediated import of bacterial T7 RNA' polymerase in the Saccharomyces cerevisiae nucleus and specific transcription of target genes [ J ]. Molecular and Cellular Biology,1990,10(1):353-60.
Non-patent document 3: wang W, Li Y, Wang Y, et al bacteriophage T7 transformation system: an engineering tool in synthetic biology [ J ] Biotechnology Advances,2018.
Non-patent document 4: Elroy-Stein O, Moss B.cytoplasmatic expression system based on constitutive synthesis of bacterial T7RNA polymerase in mammalian cells [ J ]. Proceedings of the National Academy of Sciences,1990,87(17):6743-7.
Non-patent document 5: ken Down, Michael Rosbash, T7RNA polymerase-directed transcription area processing in yeast and link 3' end formation to mRNA nuclear export [ J ] RNA,2002,8: 686. 697.
Disclosure of Invention
Problems to be solved by the invention
The invention mainly solves the problems that mRNA without a 5' cap structure transcribed by a T7 expression system in eukaryote is transported to cytoplasm across nuclear membrane to continuously, stably and efficiently express recombinant protein.
Means for solving the problems
The present inventors found that a gene encoding a Rev protein is present in the genome of human immunodeficiency virus (HIV-1) retrovirus, and that RNA that specifically binds to the Rev protein is called Rev-responsive element (RRE). Rev protein can bind RRE, inhibit splicing by interacting with splicing factors, spliceosomes, and interact with nuclear porin, transporting incompletely spliced mRNA carrying RRE from the nucleus to the cytoplasm.
The HIV-1 retrovirus also encodes a small regulatory protein in which the Vpu protein is a membrane protein formed by an oligomerization of 81 amino acids, folded into two distinct domains, an N-terminal transmembrane hydrophobic domain and a C-terminal cytoplasmic domain. With this structure, Vpu protein penetrates cell membranes in an oligomeric form to form channels, and can improve permeability of cell membranes.
The Nuclear Localization Signal (NLS) is usually a short amino acid sequence that can assist the target protein to enter the nucleus, and the introduction of the Nuclear Localization signal can make the protein enter the nucleus. When NLS is added upstream of the membrane protein, the membrane protein will localize on the nuclear membrane of the nucleus.
The present inventors have made the above-mentioned facts, and have proposed two design schemes for solving the problem of trans-nuclear membrane transport of mRNA transcribed by the T7 expression system to the cytoplasm:
1) introducing Rev-RRE regulatory elements in HIV-1 retrovirus into T7 expression system, wherein Rev protein can specifically bind RRE sequence, and mRNA lacking 5' cap structure T7RNAP transcription with RRE sequence is transported from nucleus to cytoplasm;
2) the vpu gene with nuclear localization sequence is introduced into T7 expression system, so that the protein is localized on nuclear membrane of nucleus, thereby changing permeability of nuclear membrane, and the transcription product of T7RNAP can enter cytoplasm through osmotic diffusion.
The above design scheme is not particularly limited with respect to the eukaryote to which it is applied, as long as mRNA lacking the 5' cap structure, which can achieve transcription of T7RNAP, is transported across the nuclear membrane to the cytoplasm. Preferably, it is applicable to yeast, mammals, insects. More preferably, it is applied to Saccharomyces cerevisiae (Saccharomyces cerevisiae), Pichia pastoris (Pichia pastoris), Kluyveromyces marxianus), hamster, human kidney cell, human Hela cell, CHO, COS, BHK, SP2/0, NIH3T3, silkworm, Drosophila. Most preferably, it is applied to Saccharomyces cerevisiae (Saccharomyces cerevisiae) and human Hela cells.
Preferably, the following two expression systems are used for different eukaryotes:
(one) for yeast, a T7 expression system based on Vpu of HIV-1 was constructed.
(II) for mammals, a T7 expression system based on the Vpu or Rev-RRE element of HIV-1 was constructed.
In order to verify whether the T7 expression system expresses a target protein in eukaryotes, the hygromycin resistance protein (Hph), Nanoluc luciferase (Nluc) or Enhanced Green Fluorescent Protein (EGFP) is used and is constructed in a transcription unit started by a T7 promoter.
The test proves that the reasonability of the two design schemes is proved, and the expected effect is realized by the two T7 expression systems. The result shows that the Vpu protein plays a role in changing nuclear membrane permeability, helps mRNA transcribed by T7RNAP to go out of nucleus and completes the translation process; the RRE-carrying mRNA also binds to Rev protein, helping the mRNA transcribed by T7RNAP to enucleate, completing the translation process.
Specifically, the technical scheme of the invention comprises the following steps:
[1] an expression system comprising a T7RNA polymerase and a T7 promoter, wherein said expression system comprises a Vpu protein and/or a Rev-RRE regulatory element of an HIV-1 retrovirus.
[2] The expression system according to [1], wherein the T7RNA polymerase consists of SEQ ID No: 1, and coding the sequence represented by the symbol 1.
[3] The expression system according to [1] or [2], wherein the gene of T7RNA polymerase further comprises a nuclear localization sequence.
[4] The expression system according to [3], wherein the nuclear localization sequence is SV40T-Antigen nuclear localization sequence, Nucleoplasmin nuclear localization sequence, EGL-13 nuclear localization sequence, c-Myc nuclear localization sequence or TUS-protein nuclear localization sequence.
[5] A method for expressing a protein in a eukaryote using an expression system of T7RNA polymerase and T7 promoter, characterized in that said expression system comprises the Rev-RRE regulatory element in HIV-1 retrovirus.
[6] The method according to [5], characterized in that the method comprises:
1) constructing a vector expressing T7RNA polymerase and Rev, wherein the T7RNA polymerase consists of SEQ ID No: 1, coding the sequence represented by the formula;
2) transferring a DNA fragment containing a T7 promoter, a T7 terminator, an IRES, an RRE and a target protein gene to the vector to construct a vector capable of expressing T7RNA polymerase, Rev and a target protein;
3) transfecting by using the vector constructed in the step 2) to finish slow virus packaging; and
4) infecting target eukaryotic cells with the lentivirus, obtaining a target transformant through resistance screening, and determining the expression system through verifying target protein.
[7] The method according to [5] or [6], wherein the gene of T7RNA polymerase further contains a nuclear localization sequence.
[8] The method according to [6] or [7], wherein in the step 1), a mammalian promoter is selected as a promoter for expressing T7RNA polymerase and Rev, and a eukaryotic polycistronic structure containing 2A or IRES is constructed to obtain a vector for simultaneously expressing T7RNA polymerase and Rev.
[9] The method according to any one of [6] to [8], wherein the protein of interest expressed by the expression system is verified using a hygromycin-resistant protein, Nanoluc luciferase or enhanced green fluorescent protein.
[10] The method according to any one of [5] to [9], wherein the eukaryote is a mammal.
ADVANTAGEOUS EFFECTS OF INVENTION
The invention remarkably improves the transport of mRNA lacking a 5' cap structure transcribed by T7RNAP from a cell nucleus to a cell nucleus through a transmembrane to a cytoplasm by constructing a T7 expression system based on Vpu and/or Rev-RRE elements of HIV-1, promotes the translation and synthesis of proteins, and realizes the continuous, stable and efficient expression of recombinant proteins based on a T7 expression system in eukaryotic cells.
Drawings
FIG. 1 is a diagram showing the construction of the pS-T7RNAP plasmid.
FIG. 2 is a PCR verification diagram of the construction result of Saccharomyces cerevisiae genetically engineered strain BY4741(HO:: NLS-T7 RNAP). Wherein, lane 1 is an electrophoretogram of the control bacterium BY4741 genome PCR result; lane 2 is an electropherogram of the BY4741(HO:: NLS-T7RNAP) genomic PCR results.
FIG. 3 is a diagram showing the construction of the pS-hph plasmid.
FIG. 4 is a diagram showing the construction of the pS-vpu plasmid.
FIG. 5 is a diagram showing the construction of the pS-vpu/hph plasmid.
FIG. 6 is a graph showing the effect of hygromycin on the growth rate of different recombinant strains of Saccharomyces cerevisiae. Wherein, control represents BY4741(HO:: NLS-T7RNAP, pESC-URA) strain; yhph represents the BY4741(HO:: NLS-T7RNAP, pS-hph) strain; yVpu-hph stands for BY4741(HO:: NLS-T7RNAP, pS-vpu/hph) strain.
FIG. 7 is a graph showing the effect of hygromycin on colony growth of different recombinant strains of Saccharomyces cerevisiae. Wherein, control represents BY4741(HO:: NLS-T7RNAP, pESC-URA) strain; yhph represents the BY4741(HO:: NLS-T7RNAP, pS-hph) strain; yVpu-hph represents the BY4741(HO:: NLS-T7RNAP, pS-vpu/hph) strain, hygromycin concentrations of 0. mu.g/ml, 50. mu.g/ml, 100. mu.g/ml, 150. mu.g/ml, 200. mu.g/ml, respectively.
FIG. 8 is a graph showing the effect of Vpu on the expression of Nluc in s.cerevisiae for the T7 expression system. Wherein, control represents BY4741(HO:: NLS-T7RNAP, pESC-URA) strain; yNluc stands for BY4741(HO:: NLS-T7RNAP, pS-Nluc) strain; yVpu-Nluc stands for BY4741(HO:: NLS-T7RNAP, pS-Vpu/Nluc) strain.
FIG. 9 is a graph showing the effect of Vpu on the expression of EGFP in s.cerevisiae by the T7 expression system. Wherein, control represents BY4741(HO:: NLS-T7RNAP, pESC-URA) strain; yEGFP stands for BY4741(HO:: NLS-T7RNAP, pS-EGFP) strain; yVpu-EGFP stands for BY4741(HO:: NLS-T7RNAP, pS-Vpu/EGFP) strain.
FIG. 10 is a schematic diagram of the construction of pMSCVpuro-T7RNAP and pMSCVpuro-T7RNAP-Rev plasmids.
FIG. 11 is a schematic diagram of the construction of pMSCVpuro-T7RNAP-Nluc-RRE and pMSCVpuro-T7RNAP-Rev-Nluc-RRE plasmids.
FIG. 12 is a graph showing the effect of Rev-RRE on the expression of Nluc by T7 in human Hela cell line. Wherein W is a wild-type human Hela cell line; W-T7RP is a human Hela cell line into which pMSCVpuro-T7RNAP-Rev has been introduced; W-Rev-T7RP is a human Hela cell line into which pMSCVpuro-T7RNAP-Rev-Nluc-RRE was introduced.
FIG. 13 is a schematic diagram of the construction of the pMSCVpuro-T7RNAP-Vpu plasmid.
FIG. 14 is a schematic diagram of plasmid construction of pMSCVpuro-T7RNAP-Nluc and pMSCVpuro-T7 RNAP-Vpu-Nluc.
FIG. 15 is a graph showing the effect of Vpu on the expression of Nluc by the T7 expression system in human Hela cell lines. Wherein W is a wild-type human Hela cell line; W-T7RP is a human Hela cell line introduced with pMSCVpuro-T7 RNAP-Nluc; W-Vpu-T7RP is a human Hela cell line introduced with pMSCVpuro-T7 RNAP-Vpu-Nluc.
FIG. 16 is a diagram showing the construction of the pS-Rev/EGFP/RRE plasmid.
FIG. 17 is a schematic diagram of the construction of pMSCVpuro-T7RNAP-EGFP and pMSCVpuro-T7RNAP-Rev-EGFP-RRE plasmids.
Detailed Description
The present invention is further explained by the following examples, which are only used to illustrate the present invention, and the scope of the present invention is not limited thereto.
< Experimental Material >
Carrier: pMRI 31(GenBank: KJ 502281.1); pESC-URA (GenBank: AF 063585.2); pMSCVpuro, available from Shanghai enzyme research Biotech, Inc.; pumvc, available from shanghai enzyme research biotechnology limited; pMD2.G, available from Addgene (Catalog: 12259).
The strain is as follows: saccharomyces cerevisiae strain BY4741, purchased from Invitrogen.
Cell lines: 293T cells, purchased from the institute of Biotechnology, Chuanglian, Beijing; hela cells, purchased from the institute of biotechnology, north beijing, inc.
Culture medium: YPD medium purchased from Beijing Soilebao Tech Co., Ltd; SD-URA medium purchased from Beijing Soilebao Tech Co., Ltd; DEME medium, purchased from Beijing Soilebao Tech Co., Ltd; Opti-MEM serum-reduced medium was purchased from Beijing Sorley technologies, Inc.
Reagent: fetal Bovine Serum (FBS) available from total gold biotechnology limited, beijing; 10 XPBS buffer, available from Beijing Solaibao Tech Co., Ltd;the Luciferase Assay System kit purchased from Promega Beijing Biotechnology Ltd; seamless cloning kit (Infusion) from china motai and biotechnology (beijing) ltd; fugene 9, available from beijing solibao technologies ltd; sorbitol, available from beijing solibao technologies ltd; hygromycin B, available from Beijing Solaibao Tech Co., Ltd; puromycin, available from Beijing Sorbao technologies, Inc.
< construction of plasmid and vector and method for expressing protein >
The conventional methods for constructing plasmids and vectors, expressing proteins, and packaging lentiviruses, etc., which are disclosed in the present application, can be referred to Molecular Biology and genetic methods known in the art, for example, the methods described in publications such as "conventional biological methods in the art", "Current Protocols in Molecular Biology, Wiley publication", "Molecular Cloning Manual, Cold spring harbor Laboratory publication", etc.
< example 1> construction and expression of HIV-1Vpu protein-based T7 expression System in Saccharomyces cerevisiae
Construction of pS-T7RNAP plasmid
Design and synthesis of T7RNAP (GenBank: KY484013.1) with Nuclear Localization Signal (NLS), wherein the nucleotide sequence of T7RNAP is shown as SEQ ID No: 1, the nucleotide sequence with a Nuclear Localization Signal (NLS) is shown as SEQ ID No: 2, respectively.
SEQ ID No:2:ATGCCCAAGAAGAAGCGGAAGGTC
The NLS-T7RNAP gene fragment was inserted downstream of the gal1,10 inducible promoter (GenBank: K02115.1) of pMRI 31 vector to construct a plasmid named pS-T7RNAP, and the T used CYC1 The nucleotide sequence is shown as SEQ ID No: 3, the construction process is as shown in fig. 1.
2. Construction of genetically engineered Strain BY4741(HO:: NLS-T7RNAP)
Plasmid pS-T7RNAP was linearized using the sfi I endonuclease. The linearized plasmid fragment was recovered, and then transformed into Saccharomyces cerevisiae strain BY4741, and selection of geneticin G418 resistance resulted in the recombinant strain BY4741(HO:: NLS-T7RNAP) of Saccharomyces cerevisiae, into which the T7RNAP gene was integrated. To ensure positive transformants, the genomes of the recombinant strain and the blank strain of Saccharomyces cerevisiae were extracted and verified by the specific primer HO3 to determine whether the T7RNAP gene was correctly inserted into the HO region of the Saccharomyces cerevisiae genome, the result of which is shown in FIG. 2.
The nucleotide sequence of HO3 is as follows:
HOF3:CGTGCCTGCGATGAGATAC(SEQ ID No:4)
HOR3:GGCGTATTTCTACTCCAGCA(SEQ ID No:5)
a fragment with the size of 2947bp amplified BY the control group shows no insertion fragment, while a fragment with the size of 7672bp amplified BY the experimental group shows that the T7RNAP gene is successfully inserted into a saccharomyces cerevisiae BY4741 chromosome.
3. Construction of plasmid pS-vpu/hph
Synthesis of P based on the Gene sequences provided T7 IRES-hph fragment, P T7 The sequence is SEQID No: 6, the sequence of hph is SEQ ID No: 7, T T7 The sequence is SEQ ID No: 8, the fragment is inserted into a vector pESC-URA by a seamless cloning method to complete the construction of a plasmid pS-hph, and the construction flow is shown as the figure 3. Meanwhile, a vpu gene (shown as SEQ ID No: 9) carrying a Nuclear Localization Sequence (NLS) was inserted into the downstream of the gal bidirectional promoter in the vector pESC-URA to construct a plasmid pS-vpu, the construction flow of which is shown in FIG. 4.
Amplification of P Using plasmid pS-hph as template T7 IRES-hph DNA fragment, the primers used are as follows:
F:TCAAGGAGAAAAAACCAAAAAACCCCTCAAGGCCC(SEQ ID No:
10)
R:TTAATGCAGCTGGATTAATACGACTCACTATAGGT(SEQ ID No:11)
finally P to be recovered T7 The IRES-hph fragment was inserted into the plasmid vector pS-vpu by the same method of seamless cloning to construct the plasmid pS-vpu/hph, and the vector construction process is shown in FIG. 5.
4. Construction of genetically engineered Strain BY4741(HO:: NLS-T7RNAP, pS-vpu/hph)
And transferring the final target plasmid pS-vpu/hph into saccharomyces cerevisiae BY4741(HO:: NLS-T7RNAP) to obtain a saccharomyces cerevisiae recombinant strain BY4741(HO:: NLS-T7RNAP, pS-vpu/hph). The specific operation refers to the following steps of saccharomyces cerevisiae competence preparation and transformation.
The preparation process of the saccharomyces cerevisiae competence is as follows:
(1) single yeast colonies were picked from the plates and cultured in 5mL YPD liquid medium at 30 ℃ for 12 hours. Then, 500. mu.L of the culture medium was aspirated to 50mL of YPD liquid medium, and the medium was further cultured at 30 ℃ for 18-24 hours to OD 600 About 2.
(2) Transferring the bacterial liquid to a sterilized 50ml centrifuge tube, centrifuging at 5000rpm for 5min, removing supernatant, then re-suspending the thalli with 30ml of precooled sterile water, and centrifuging at 5000rpm for 5min to remove supernatant.
(3) The cells were resuspended in 20ml of precooled and sterilized 1M sorbitol and the supernatant removed. And finally, transferring the 1M sorbitol heavy suspension cells with 200-500 mul to a 1.5ml centrifuge tube to obtain the saccharomyces cerevisiae competent cells. Fresh competence is required to be prepared each time yeast transformation is performed to ensure high transformation rate.
The saccharomyces cerevisiae electrotransformation steps are as follows:
(1) and (3-5) mu L of linear plasmid or plasmid (the concentration is more than or equal to 300 ng/mu L) and 40 mu L of saccharomyces cerevisiae competent cells are uniformly mixed in a precooled 1.5mL centrifuge tube, transferred into a 2mm electric transfer cup and precooled on ice for 5 min.
(2) The water drops on the electric revolving cup are wiped off with paper, and the electric revolving apparatus is adopted to shock under the electric shock strength of 1500V.
(3) 1mL of YPD medium was added to an electric rotor, and the mixture was transferred to a sterilized 1.5mL centrifuge tube by gentle suspension and allowed to stand at 30 ℃ for 2 hours for recovery. After recovery, the cells were washed 3 times with sterile water and plated on appropriate plates. The culture was incubated at 30 ℃ for 2-3 days until single colonies appeared.
5. Detection of recombinant protein expression effect of constructed T7 expression system in saccharomyces cerevisiae
The expression of the T7RNAP gene is controlled by a Gal promoter which needs to be expressed under the induction condition of taking galactose as a carbon source, so that the recombinant strain of the saccharomyces cerevisiae can be firstly cultured in SD-URA for 24h and then induced and cultured for 48h by SG-URA, otherwise, T7RNA polymerase does not participate in the T7 expression system to play the self function.
Expression detection of hygromycin resistance protein (Hph) reporter gene in saccharomyces cerevisiae recombinant strain
< growth Rate of Strain >
The vectors pESC-URA and pS-hph were transferred into recombinant strain BY4741 of Saccharomyces cerevisiae (HO:: NLS-T7RNAP) according to the method of 4 in example 1, to obtain control strain BY4741(HO:: NLS-T7RNAP, pESC-URA) and strain BY4741(HO:: NLS-T7RNAP, pS-hph), respectively. These two control and experimental group strains BY4741(HO:: NLS-T7RNAP, pS-vpu/hph) were cultured in SD-URA liquid medium for 24 hours, and OD was adjusted BY dilution 600 OD of three strains 600 The values are consistent, inoculating the strain to SG-URA liquid culture medium according to 1% transfer quantity, adding hygromycin with the final concentration of 400 mu g/ml, and measuring the OD of the strain liquid every 12h 600 The amount of the expressed resistance protein was reflected by the growth of the strain, and the results are shown in FIG. 6.
As can be seen from FIG. 6, the control strain BY4741(HO:: NLS-T7RNAP, pESC-URA) (denoted BY control) did not grow substantially at a hygromycin concentration of 400. mu.g/ml, and the strain BY4741(HO:: NLS-T7RNAP, pS-vpu/hph) (denoted BY yVpu-hph) carrying the vpu gene grew faster than the strain BY4741(HO:: NLS-T7RNAP, pS-hph) (denoted BY yhph) not carrying the vpu gene, indicating that the strain carrying the vpu gene expressed more resistance protein and thus grew faster. The experimental result shows that the T7 expression system containing Vpu protein utilizes Vpu protein to improve the permeability of nuclear membrane of cell nucleus, so that more mRNA transcribed by T7RNAP is transported to cytoplasm, the translation process is completed, and more resistance protein is synthesized.
< colony size and growth status >
Culturing Saccharomyces cerevisiae BY4741(HO:: NLS-T7RNAP, pESC-URA), recombinant strain BY4741(HO:: NLS-T7RNAP, pS-hph) and recombinant strain BY4741(HO:: NLS-T7RNAP, pS-vpu/hph) in SD-URA liquid culture medium for 24h, and diluting to adjust the thallus concentration of the three strains to make the OD of the three strains 600 The values remained consistent, and the diluted inoculum was spotted on SG-URA solid plates containing different concentrations of hygromycin, which were 0. mu.g/ml, 50. mu.g/ml, 100. mu.g/ml, 150. mu.g/ml and 200. mu.g/ml in this order (see FIG. 7, the uppermost digit represents the concentration of hygromycin). The size and growth state of colonies were observed after 3 days, and the results are shown in FIG. 7.
As can be seen from FIG. 7, the strain grew normally at a hygromycin concentration of 0. mu.g/ml; with increasing hygromycin concentration, BY4741(HO:: NLS-T7RNAP, pESC-URA), which does not carry a resistance gene, is inhibited from growing until it fails to grow, expressed as control. BY4741(HO:: NLS-T7RNAP, pS-Vpu/hph) carrying Vpu gene (expressed as yVpu-hph) has more colonies than BY4741(HO:: NLS-T7RNAP, pS-hph) not carrying Vpu gene (expressed as yhph), which indicates that the introduction of Vpu protein can improve the permeability of nuclear membrane, so that more mRNA transcribed BY T7RNAP passes through the nuclear membrane into cytoplasm to synthesize hygromycin-resistant protein.
NanoLuc TM Detection of luciferase (Nluc) reporter Gene expression in recombinant Saccharomyces cerevisiae strains
Plasmids and recombinant strains of Saccharomyces cerevisiae were constructed BY the methods of 3 and 4 in example 1 to obtain yeast strains BY4741(HO:: NLS-T7RNAP, pESC-URA), BY4741(HO:: NLS-T7RNAP, pS-Nluc), BY4741(HO:: NLS-T7RNAP, pS-Vpu/Nluc). The nucleotide sequence of Nluc is shown as SEQ ID No: shown at 12.
The three strains are respectively subjected to the following operations: culturing in SD-URA liquid culture medium for 24 hr, inoculating to SG-URA liquid culture medium according to 1% inoculum size, culturing to a certain concentration, centrifuging, collecting thallus, washing with filter sterilized PBS for 3 times, and suspending in sterile PBS.
The detection method comprises the following steps: reacting Nano-Glo TM Substrate and lysis buffer provided with kit diluted at 1:50 and mixed with yeast cells at 1:10, transferring 200. mu.l of sample to white 96-well plate, immediately using Luminence mode of multifunctional microplate reader to determine bioluminescence intensity, transferring 200. mu.l of sample to 96-well transparent plate for determining OD 600 . To compare the differences between different bacteria, the mean bioluminescence intensity in the experiment was divided by the OD 600 . The sample is diluted to the appropriate concentration (OD) prior to measurement 600 0.3 to 0.8), the results are shown in fig. 8.
As can be seen in FIG. 8, the bioluminescent signal was not substantially detected in the control strain containing no luciferase gene (denoted BY control), and the bioluminescent intensity of the strain BY4741 carrying the Vpu gene (HO:: NLS-T7RNAP, pS-Vpu/Nluc) (denoted BY yVpu-Nluc) was 2.0 times higher than that of the strain BY4741 not carrying the Vpu gene (HO:: NLS-T7RNAP, pS-Nluc) (denoted BY yNluc). The result shows that the Vpu protein improves the permeability of nuclear membranes of cell nuclei, thereby promoting the mRNA transcribed by T7RNAP to be transported to cytoplasm through membrane, so that more protein is synthesized than a T7 expression system not carrying the Vpu protein, and the aim of efficiently expressing recombinant protein is fulfilled.
Expression detection of Enhanced Green Fluorescent Protein (EGFP) reporter gene in recombinant saccharomyces cerevisiae strain
Plasmids and recombinant strains of Saccharomyces cerevisiae were constructed in accordance with the methods of 3 and 4 in example 1 to obtain yeast strains BY4741(HO:: NLS-T7RNAP, pESC-URA), BY4741(HO:: NLS-T7RNAP, pS-EGFP) and BY4741(HO:: NLS-T7RNAP, pS-Vpu/EGFP). The nucleotide sequence of EGFP is shown as SEQ ID No: shown at 13.
The three strains were subjected to the following operations: after culturing in SD-URA liquid culture medium for 24h, transferring to SG-URA liquid culture medium according to 1% inoculum size, culturing to a certain concentration, centrifuging, collecting thallus, washing with sterile water for 3 times, suspending in sterile water, and detecting fluorescent gene expression by a multifunctional microplate reader, wherein the results are shown in Table 1 and FIG. 9.
TABLE 1 mean fluorescence intensity of different Saccharomyces cerevisiae recombinant strains
In Table 1, control represents BY4741(HO:: NLS-T7RNAP, pESC-URA) strain; yEGFP stands for BY4741(HO:: NLS-T7RNAP, pS-EGFP) strain; yVpu-EGFP stands for BY4741(HO:: NLS-T7RNAP, pS-Vpu/EGFP) strain.
As can also be seen from FIG. 9, the fluorescence intensity of BY4741(HO:: NLS-T7RNAP, pS-Vpu/EGFP) strain is significantly higher than that of BY4741(HO:: NLS-T7RNAP, pESC-URA) strain and BY4741(HO:: NLS-T7RNAP, pS-EGFP), indicating that Vpu protein increases the permeability of nuclear membrane of nucleus, thereby promoting the transport of mRNA transcribed BY T7RNAP into cytoplasm through membrane, and therefore synthesizing more protein than T7 expression system without Vpu protein, and achieving the purpose of efficiently expressing recombinant protein.
< example 2> construction and expression of T7 expression System based on HIV-1Rev-RRE regulatory element in mammalian cells
1. Construction of Lentiviral expression vector pMSCVpuro-T7RNAP-Rev-Nluc-RRE
The promoter of human phosphoglycerate kinase 1(PGK1) gene (shown as SEQ ID No: 14) is selected as the promoter for expressing T7RNAP and Rev, the co-expression of T7RNAP and Rev (shown as SEQ ID No: 15) proteins is realized by connecting 2A (shown as SEQ ID No: 16) or IRES (shown as SEQ ID No: 17), and pMSCVpuro-T7RNAP-Rev plasmids are finally constructed. Taking the 2A connection as an example, the construction flow is shown in fig. 10.
Respectively synthesizing PGK1, NLS-T7RNAP, SV40poly (A) (shown as SEQ ID No: 18) and 2A-Rev-SV40poly (A) fragments, fusing the fragments by adopting a fusion PCR technology to obtain large fragments of PGK1-T7RNAP-SV40 poly (A) and PGK1-T7RNAP-2A-Rev-SV40poly (A), and finally transferring the DNA fragments of PGK1-T7RNAP-SV40 poly (A) and PGK1-T7RNAP-2A-Rev-SV40poly (A) to a lentivirus expression vector pMSCUro to complete the construction of plasmids pMSCVpuro-T7RNAP and pMSCuro-T7 RNAP-Rev.
Synthesis of P T7 -IRES-Nluc-RRE fragment, RRE sequence SEQ ID No: 19, or a sequence shown in seq id no. Finally, the DNA fragment P is added T7 And transferring the IRES-Nluc-RRE to vectors pMSCVpuro-T7RNAP and pMSCVpuro-T7RNAP-Rev to complete the construction of plasmids pMSCVpuro-T7RNAP-Nluc-RRE and pMSCVpuro-T7RNAP-Rev-Nluc-RRE, wherein the specific construction flow is shown in figure 11.
2.293 packaging lentivirus from T cell, infecting human Hela cell
The vectors pMSCVpuro-T7RNAP-Nluc-RRE and pMSCVpuro-T7RNAP-Rev-Nluc-RRE constructed above are transfected into 293T cells to complete lentivirus packaging. Successfully transformed transformants were selected by puromycin. For specific manipulations, reference is made to the following procedure for packaging of 293T cells with lentiviruses and for infecting cells of interest with lentiviruses.
The 293T cell packaging lentivirus process is as follows:
(1) when the cells grew to nonagorean, the cell culture medium was discarded, gently rinsed once with sterile PBS, and digested with 1ml of 0.25% pancreatin. After the cells were observed to be digested and rounded under a microscope, the pancreatic enzymes were discarded, the 293T cells were resuspended in a 10% FBS-containing DMEM medium, and the number of 5X 10 cells was counted 5 Individual cells were divided into each well of a 6-well cell culture plate.
(2) After 24h, 293T cells were transfected:
a: 30ul of Fugene 9 was diluted with 470. mu.l of Opti-MEM, gently mixed well, and allowed to stand at room temperature for 5 min.
B: preparing a target plasmid and a packaging vector plasmid:
two packaging vector plasmids, pUMVC: 1 mu g of the solution; pmd2. g: 0.5. mu.g
Target plasmid: 1 μ g.
C: dropwise adding the prepared plasmid mixture into a mixed solution of Opti-MEM and Fugene 9, and standing at room temperature for 20 min; to each well of a 6-well plate inoculated with cells and containing 100. mu.l of medium, 2 to 10. mu.l of the above mixture was added. And (4) blowing and sucking or shaking by using a shaker for 10-30 s for uniformly mixing, and putting the cells back into the incubator for continuous culture.
D: after 6-8 h, the 293T cells were changed, and the cells were placed in a 37 ℃ cell incubator for further culture for 48h without blowing up the cells (by gently adding new culture medium along the dish wall) when the liquid was added.
(3) Plating of target cells:
the cells of interest need to be plated one day in advance into six-well cell culture plates (the number of cell inoculations is 2X 10) 5 ~3×10 5 One) to ensure that the density is 30-40% during infection; a control group not infected with the virus was also prepared. The following day the supernatant was discarded and virus-containing medium was added for infection.
(4) Collecting slow virus liquid:
48h after transfection (this time with 293T cells), the supernatant was collected in a 15ml centrifuge tube, centrifuged at 3000rpm for 20min and the supernatant was filtered through a 0.45 μm filter tip. Adding appropriate amount of culture solution into six-well plate, collecting supernatant after 24 hr, subpackaging according to dosage, and storing in-80 deg.C refrigerator.
The steps for lentivirus infection of the cells of interest (human Hela cells) are as follows:
(1) preparing 3ml of culture medium 1640 (10% FBS), adding 3ml of virus supernatant (storing the rest virus supernatant in a refrigerator at-80 ℃), supplementing 4ml of 1640 culture solution after 24 hours, and ensuring that cells are in a good state;
(2) placing the cell culture plate in a cell culture box for further culture for 24 hours;
(3) after 48 hours, discarding the supernatant, replacing 6-8 ml of fresh culture medium, adding puromycin with corresponding concentration for screening, and killing cells which are not transferred into DNA;
(4) after 72h, cells with all dead negative control groups and proper amount of viable transfected DNA groups are selected for monoclonal culture, and the cells in the holes are divided into single cells by a limiting dilution method to be cultured in a 96-well plate for cell culture.
(5) Culturing for about 10 days, selecting cell monoclone, and detecting.
3. And (3) detecting the effect of the constructed T7 expression system on recombinant protein expression in mammalian cells.
Expression detection of Nluc reporter gene in human Hela cell line
Wild human Hela cell line was used as a control, wild Hela cells and lentivirus-infected cells were trypsinized to suspension, washed 3 times with sterile PBS, and the cells were resuspended in sterile PBS.
The detection method comprises the following steps: will be provided withThe substrate and lysis buffer provided in the kit were diluted 1:50 and mixed with the cells in a ratio of 1:10, 200. mu.l of the sample was transferred to a white 96-well plate, and bioluminescence was immediately measured using the luciferase mode of a multi-functional microplate reader, the results of which are shown in FIG. 12.
As can be seen from FIG. 12, substantially no bioluminescent signal was detected from the wild-type human Hela cell line (denoted by W). The bioluminescence intensity of the human Hela cell strain (represented by W-Rev-T7 RP) carrying the Rev-RRE element is 4.3 times of that of the human Hela cell strain (represented by W-T7 RP) not carrying the Rev-RRE element, which indicates that mRNA carrying the RRE element can be combined with Rev protein to promote the nuclear extraction of mRNA transcribed by T7RNAP, complete the translation process and continuously and stably express the target protein.
< example 3> construction and expression of HIV-1Vpu protein-based T7 expression System in mammalian cells
1. Construction of Lentiviral expression vector pMSCVpuro-T7RNAP-Vpu-NLuc
The promoter PGK1 of the human phosphoglycerate kinase gene is selected as the promoter for expressing T7RNAP and Vpu, the expression of T7RNAP and Vpu protein is realized by 2A or IRES connection, and pMSCVpuro-T7RNAP-Vpu is finally constructed. Taking the 2A connection as an example, the construction flow is shown in fig. 13.
Respectively synthesizing fragments PGK1, NLS-T7RNAP and 2A-Vpu-NLS-SV40 poly (A), fusing the three fragments by adopting a fusion PCR technology to obtain a large fragment PGK1-T7RNAP-2A-Vpu-SV40poly (A), and finally transferring the DNA fragment PGK1-T7RNAP-2A-Vpu-SV40poly (A) to a lentivirus expression vector pMSCVpuro by a seamless cloning method to complete the construction of the plasmid pMSCVpuro-T7 RNAP-Vpu.
Synthesis of P T7 IRES-Nluc fragment, DNA fragment P by means of seamless cloning T7 IRES-Nluc was transferred to the vectors pMSCVpuro-T7RNAP and pMSCVpuro-T7RNAP-Vpu, and the construction of the plasmids pMSCVpuro-T7RNAP-Nluc and pMSCVpuro-T7RNAP-Vpu-Nluc was completed, and the specific construction flow is shown in FIG. 14.
2.293 packaging lentivirus from T cell, infecting human Hela cell
The vectors constructed above, pMSCVpuro-T7RNAP-Nluc and pMSCVpuro-T7RNAP-Vpu-Nluc, were transfected into 293T cells to complete lentiviral packaging. Transformants successfully transformed by puromycin screening were specifically manipulated according to the procedure of example 2 in which 293T cells were packaged with lentivirus and the lentivirus infected cells of interest.
3. And (3) detecting the effect of the constructed T7 expression system on the expression of the recombinant protein in mammalian cells.
Expression detection of Nluc reporter gene in human Hela cells
The wild human Hela cell line was used as a control, wild human Hela cells and lentivirus-infected cells were trypsinized to suspension, washed 3 times with sterile PBS, and the cells were resuspended in sterile PBS.
The detection method comprises the following steps: will be provided withThe substrate was diluted 1:50 with lysis buffer provided in the kit and mixed with cells at a ratio of 1:10, 200. mu.l of the sample was transferred to a white 96-well plate, and bioluminescence was immediately measured using the Luminescene mode of a multifunctional microplate reader, the results of which are shown in FIG. 15.
As can be seen from FIG. 15, substantially no bioluminescent signal was detected from the wild-type human Hela cell line (denoted by W). The bioluminescence intensity of the human Hela cell strain (represented by W-Vpu-T7 RP) carrying the Vpu protein is 4.5 times of the bioluminescence intensity of the human Hela cell strain (represented by W-T7 RP) not carrying the Vpu protein, which shows that the Vpu protein can improve the nuclear membrane permeability of cell nuclei, help the mRNA transcribed by T7RNAP to go out of the nuclei, complete the translation process and realize the continuous, stable and high-efficiency expression of the target protein.
< example 4> difference in protein expression in Saccharomyces cerevisiae and human Hela cells by Rev-RRE-based T7 expression System
Referring to example 1 to construct a Rev-RRE-based T7 expression system suitable for s.cerevisiae, a Rev gene fragment (see, SEQ ID No: 3 in the sequence Listing) was first inserted downstream of the pESC-URAgal bidirectional promoter to construct a plasmid vector pS-Rev. Synthesis of P T7 IRES-EGFP-RRE fragment, and the above fragment was inserted into plasmid pS-Rev by a seamless cloning method to construct plasmid pS-Rev/EGFP/RRE, the vector construction process being shown in FIG. 16. Saccharomyces cerevisiae strain BY4741(HO:: NLS-T7RNAP, pS-Rev/EGFP/RRE) was constructed BY reference to method 4 in example 1. Referring to example 2, a Rev-RRE-based T7 expression vector pMSCVpuro-T7RNAP-Rev-EGFP-RRE suitable for human Hela cells was constructed using EGFP as a reporter gene, and the construction process is shown in FIG. 17. The effect of the Rev-RRE regulatory element-based T7 expression system on recombinant protein expression in Saccharomyces cerevisiae and human Hela cells was compared as determined in example 1 using Enhanced Green Fluorescent Protein (EGFP) as a reporter gene, and the results are shown in Table 2.
TABLE 2 mean fluorescence intensity of Saccharomyces cerevisiae and human Hela cells
In Table 2, control 1 represents Saccharomyces cerevisiae BY4741(HO:: NLS-T7RNAP, pESC-URA) strain; control 2 represents wild human Hela cell line; yRev-RRE-EGFP represents Saccharomyces cerevisiae BY4741(HO:: NLS-T7RNAP, pS-Rev/EGFP/RRE) strain; W-T7RP-Rev-EGFP-RRE represents the human Hela cell strain introduced with pMSCVpuro-T7 RNAP-Rev-EGFP-RRE.
As can be seen from Table 2, the T7 expression system based on Rev-RRE regulatory element has little difference in fluorescence intensity between Control 1 and yRev-RRE-EGFP in Saccharomyces cerevisiae, which indicates that yRev-RRE-EGFP has no green fluorescent protein expression. In human Hela cells, the fluorescence intensity of W-T7RP-Rev-EGFP-RRE is 21.3 times that of Control 2, which shows that the protein expression of the T7 expression system based on Rev-RRE element is better than that of Saccharomyces cerevisiae in mammalian cells.
Industrial applicability
The application develops an expression system for producing proteins by eukaryotes, and the mRNA transcribed by T7RNAP and lacking a 5' cap structure is transported to cytoplasm by the HIV-1Vpu membrane protein and Rev-RRE regulatory element, so that the recombinant protein can be continuously, stably and efficiently expressed in eukaryotic cells.
Sequence listing
<110> Beijing university of chemical industry
<120> an expression system of T7RNA polymerase and T7 promoter and method for expressing protein in eukaryote using the same
<160> 19
<170> SIPOSequenceListing 1.0
<210> 1
<211> 2652
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
atgaacacga ttaacatcgc taagaacgac ttctctgaca tcgaactggc tgctatcccg 60
ttcaacactc tggctgacca ttacggtgag cgtttagctc gcgaacagtt ggcccttgag 120
catgagtctt acgagatggg tgaagcacgc ttccgcaaga tgtttgagcg tcaacttaaa 180
gctggtgagg ttgcggataa cgctgccgcc aagcctctca tcactaccct actccctaag 240
atgattgcac gcatcaacga ctggtttgag gaagtgaaag ctaagcgcgg caagcgcccg 300
acagccttcc agttcctgca agaaatcaag ccggaagccg tagcgtacat caccattaag 360
accactctgg cttgcctaac cagtgctgac aatacaaccg ttcaggctgt agcaagcgca 420
atcggtcggg ccattgagga cgaggctcgc ttcggtcgta tccgtgacct tgaagctaag 480
cacttcaaga aaaacgttga ggaacaactc aacaagcgcg tagggcacgt ctacaagaaa 540
gcatttatgc aagttgtcga ggctgacatg ctctctaagg gtctactcgg tggcgaggcg 600
tggtcttcgt ggcataagga agactctatt catgtaggag tacgctgcat cgagatgctc 660
attgagtcaa ccggaatggt tagcttacac cgccaaaatg ctggcgtagt aggtcaagac 720
tctgagacta tcgaactcgc acctgaatac gctgaggcta tcgcaacccg tgcaggtgcg 780
ctggctggca tctctccgat gttccaacct tgcgtagttc ctcctaagcc gtggactggc 840
attactggtg gtggctattg ggctaacggt cgtcgtcctc tggcgctggt gcgtactcac 900
agtaagaaag cactgatgcg ctacgaagac gtttacatgc ctgaggtgta caaagcgatt 960
aacattgcgc aaaacaccgc atggaaaatc aacaagaaag tcctagcggt cgccaacgta 1020
atcaccaagt ggaagcattg tccggtcgag gacatccctg cgattgagcg tgaagaactc 1080
ccgatgaaac cggaagacat cgacatgaat cctgaggctc tcaccgcgtg gaaacgtgct 1140
gccgctgctg tgtaccgcaa ggacaaggct cgcaagtctc gccgtatcag ccttgagttc 1200
atgcttgagc aagccaataa gtttgctaac cataaggcca tctggttccc ttacaacatg 1260
gactggcgcg gtcgtgttta cgctgtgtca atgttcaacc cgcaaggtaa cgatatgacc 1320
aaaggactgc ttacgctggc gaaaggtaaa ccaatcggta aggaaggtta ctactggctg 1380
aaaatccacg gtgcaaactg tgcgggtgtc gataaggttc cgttccctga gcgcatcaag 1440
ttcattgagg aaaaccacga gaacatcatg gcttgcgcta agtctccact ggagaacact 1500
tggtgggctg agcaagattc tccgttctgc ttccttgcgt tctgctttga gtacgctggg 1560
gtacagcacc acggcctgag ctataactgc tcccttccgc tggcgtttga cgggtcttgc 1620
tctggcatcc agcacttctc cgcgatgctc cgagatgagg taggtggtcg cgcggttaac 1680
ttgcttccta gtgaaaccgt tcaggacatc tacgggattg ttgctaagaa agtcaacgag 1740
attctacaag cagacgcaat caatgggacc gataacgaag tagttaccgt gaccgatgag 1800
aacactggtg aaatctctga gaaagtcaag ctgggcacta aggcactggc tggtcaatgg 1860
ctggcttacg gtgttactcg cagtgtgact aagcgttcag tcatgacgct ggcttacggg 1920
tccaaagagt tcggcttccg tcaacaagtg ctggaagata ccattcagcc agctattgat 1980
tccggcaagg gtctgatgtt cactcagccg aatcaggctg ctggatacat ggctaagctg 2040
atttgggaat ctgtgagcgt gacggtggta gctgcggttg aagcaatgaa ctggcttaag 2100
tctgctgcta agctgctggc tgctgaggtc aaagataaga agactggaga gattcttcgc 2160
aagcgttgcg ctgtgcattg ggtaactcct gatggtttcc ctgtgtggca ggaatacaag 2220
aagcctattc agacgcgctt gaacctgatg ttcctcggtc agttccgctt acagcctacc 2280
attaacacca acaaagatag cgagattgat gcacacaaac aggagtctgg tatcgctcct 2340
aactttgtac acagccaaga cggtagccac cttcgtaaga ctgtagtgtg ggcacacgag 2400
aagtacggaa tcgaatcttt tgcactgatt cacgactcct tcggtaccat tccggctgac 2460
gctgcgaacc tgttcaaagc agtgcgcgaa actatggttg acacatatga gtcttgtgat 2520
gtactggctg atttctacga ccagttcgct gaccagttgc acgagtctca attggacaaa 2580
atgccagcac ttccggctaa aggtaacttg aacctccgtg acatcttaga gtcggacttc 2640
gcgttcgcgt aa 2652
<210> 2
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
atgcccaaga agaagcggaa ggtc 24
<210> 3
<211> 246
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
ttatgtcacg cttacattca cgccctcccc ccacatccgc tctaaccgaa aaggaaggag 60
ttagacaacc tgaagtctag gtccctattt atttttttat agttatgtta gtattaagaa 120
cgttatttat atttcaaatt tttctttttt ttctgtacag acgcgtgtac gcatgtaaca 180
ttatactgaa aaccttgctt gagaaggttt tgggacgctc gaaggcttta atttgcggcc 240
ggtacc 246
<210> 4
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
cgtgcctgcg atgagatac 19
<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ggcgtatttc tactccagca 20
<210> 6
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
taatacgact cactatagg 19
<210> 7
<211> 1026
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
atgaaaaagc ctgaactcac cgcgacgtct gtcgagaagt ttctgatcga aaagttcgac 60
agcgtctccg acctgatgca gctctcggag ggcgaagaat ctcgtgcttt cagcttcgat 120
gtaggagggc gtggatatgt cctgcgggta aatagctgcg ccgatggttt ctacaaagat 180
cgttatgttt atcggcactt tgcatcggcc gcgctcccga ttccggaagt gcttgacatt 240
ggggaattca gcgagagcct gacctattgc atctcccgcc gtgcacaggg tgtcacgttg 300
caagacctgc ctgaaaccga actgcccgct gttctgcagc cggtcgcgga ggccatggat 360
gcgatcgctg cggccgatct tagccagacg agcgggttcg gcccattcgg accgcaagga 420
atcggtcaat acactacatg gcgtgatttc atatgcgcga ttgctgatcc ccatgtgtat 480
cactggcaaa ctgtgatgga cgacaccgtc agtgcgtccg tcgcgcaggc tctcgatgag 540
ctgatgcttt gggccgagga ctgccccgaa gtccggcacc tcgtgcacgc ggatttcggc 600
tccaacaatg tcctgacgga caatggccgc ataacagcgg tcattgactg gagcgaggcg 660
atgttcgggg attcccaata cgaggtcgcc aacatcttct tctggaggcc gtggttggct 720
tgtatggagc agcagacgcg ctacttcgag cggaggcatc cggagcttgc aggatcgccg 780
cggctccggg cgtatatgct ccgcattggt cttgaccaac tctatcagag cttggttgac 840
ggcaatttcg atgatgcagc ttgggcgcag ggtcgatgcg acgcaatcgt ccgatccgga 900
gccgggactg tcgggcgtac acaaatcgcc cgcagaagcg cggccgtctg gaccgatggc 960
tgtgtagaag tactcgccga tagtggaaac cgacgcccca gcactcgtcc gagggcaaag 1020
gaatag 1026
<210> 8
<211> 48
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
ctagcataac cccttggggc ctctaaacgg gccttgaggg gttttttg 48
<210> 9
<211> 243
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
atgcaaccta tacaaatagc aatagtagca ttagtagtag caataataat agcaatagtt 60
gtgtggtcca tagtaatcat agaatatagg aaaatattaa gacaaagaaa aatagacagg 120
ttaattgata gactaataga aagagcagaa gacagtggca atgagagtga aggaaaaata 180
tcagcacttg tggagatggg ggtggagatg gggcaccatg ctccttggga tgttgatgat 240
ctg 243
<210> 10
<211> 35
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
tcaaggagaa aaaaccaaaa aacccctcaa ggccc 35
<210> 11
<211> 35
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
ttaatgcagc tggattaata cgactcacta taggt 35
<210> 12
<211> 516
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
atggtcttca cactcgaaga tttcgttggg gactggcgac agacagccgg ctacaacctg 60
gaccaagtcc ttgaacaggg aggtgtgtcc agtttgtttc agaatctcgg ggtgtccgta 120
actccgatcc aaaggattgt cctgagcggt gaaaatgggc tgaagatcga catccatgtc 180
atcatcccgt atgaaggtct gagcggcgac caaatgggcc agatcgaaaa aatttttaag 240
gtggtgtacc ctgtggatga tcatcacttt aaggtgatcc tgcactatgg cacactggta 300
atcgacgggg ttacgccgaa catgatcgac tatttcggac ggccgtatga aggcatcgcc 360
gtgttcgacg gcaaaaagat cactgtaaca gggaccctgt ggaacggcaa caaaattatc 420
gacgagcgcc tgatcaaccc cgacggctcc ctgctgttcc gagtaaccat caacggagtg 480
accggctggc ggctgtgcga acgcattctg gcgtaa 516
<210> 13
<211> 795
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
atgtctaaag gtgaagaatt attcactggt gttgtcccaa ttttggttga attagatggt 60
gatgttaatg gtcacaaatt ttctgtctcc ggtgaaggtg aaggtgatgc tacttacggt 120
aaattgacct taaaatttat ttgtactact ggtaaattgc cagttccatg gccaacctta 180
gtcactactt tcggttatgg tgttcaatgt tttgctagat acccagatca tatgaaacaa 240
catgactttt tcaagtctgc catgccagaa ggttatgttc aagaaagaac tatttttttc 300
aaagatgacg gtaactacaa gaccagagct gaagtcaagt ttgaaggtga taccttagtt 360
aatagaatcg aattaaaagg tattgatttt aaagaagatg gtaacatttt aggtcacaaa 420
ttggaataca actataactc tcacaatgtt tacatcatgg ctgacaaaca aaagaatggt 480
atcaaagtta acttcaaaat tagacacaac attgaagatg gttctgttca attagctgac 540
cattatcaac aaaatactcc aattggtgat ggtccagtct tgttaccaga caaccattac 600
ttatccactc aatctgcctt atccaaagat ccaaacgaaa agagagacca catggtcttg 660
ttagaatttg ttactgctgc tggtattacc catggtatgg atgaattgta caaatctaga 720
actagtggat cccccgggct gcaggaattc gatatcaagc ttatcgatac cgtcgacctc 780
gagtcatgta attag 795
<210> 14
<211> 500
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
gggtagggga ggcgcttttc ccaaggcagt ctggagcatg cgctttagca gccccgctgg 60
gcacttggcg ctacacaagt ggcctctggc ctcgcacaca ttccacatcc accggtaggc 120
gccaaccggc tccgttcttt ggtggcccct tcgcgccacc ttctactcct cccctagtca 180
ggaagttccc ccccgccccg cagctcgcgt cgtgcaggac gtgacaaatg gaagtagcac 240
gtctcactag tctcgtgcag atggacagca ccgctgagca atggaagcgg gtaggccttt 300
ggggcagcgg ccaatagcag ctttgctcct tcgctttctg ggctcagagg ctgggaaggg 360
gtgggtccgg gggcgggctc aggggcgggc tcaggggcgg ggcgggcgcc cgaaggtcct 420
ccggaggccc ggcattctgc acgcttcaaa agcgcacgtc tgccgcgctg ttctcctctt 480
cctcatctcc gggcctttcg 500
<210> 15
<211> 348
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
atggcaggaa gaagcggaga cagcgacgaa gaactcctca aggcagtcag actgatcaag 60
tttctctacc aaagcaaccc acctcccagc ccagagggga cccgacaggc ccgaaggaat 120
cgaagaagaa ggtggagaga gagacagaga cagatccgag cacttagtgg atggattctt 180
agcactcatc tgggtcgatc tgcggagcct gtgcctcttc agctaccacc gcttgagaga 240
cttactcttg attgtaacga ggattgtgga aattctggga cgcagggggt gggaaatcat 300
caagtattgg tggagtctcc tacaatattg gagtcaggaa ctaaagaa 348
<210> 16
<211> 51
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
aattttgacc tgctcaagtt ggccggagac gttgagtcca accctgggcc c 51
<210> 17
<211> 627
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 17
tgtttattca agtggaagca gatttgtacg ctcaagcggt tgaataaact agttaacgtt 60
actggccgaa gtcgcttgga ataaggccgg tgtgcgtttg tctatatgtt attttccacc 120
atattgccgt cttttggcaa tgtgagggcc cggaaacctg gccctgtctt cttgacgagc 180
attcctaggg gtctttcccc tctcgccaaa ggaatgcaag gtctgttgaa tgtcgtgaag 240
gaagcagttc ctctggaagc ttcttgaaga caaacaacgt ctgtagcgac cctttgcagg 300
cagcggaacc ccccacctgg cgacaggtgc ctctgcggcc aaaagccacg tgtataagat 360
acacctgcaa aggcggcaca accccagtgc cacgttgtga gttggatagt tgtggaaaga 420
gtcaaatggc tctcctcaag cgtattcaac aaggggctga aggatgccca gaaggtaccc 480
cattgtatgg gatctgatct ggggcctcgg tgcacatgct ttacatgtgt ttagtcgagg 540
ttaaaaaaac gtctaggccc cccgaaccac ggggacgtgg ttttcctttg aaaaacacga 600
tgataatatg gccacaacgt cgatatg 627
<210> 18
<211> 122
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 18
aacttgttta ttgcagctta taatggttac aaataaagca atagcatcac aaatttcaca 60
aataaagcat ttttttcact gcattctagt tgtggtttgt ccaaactcat caatgtatct 120
ta 122
<210> 19
<211> 234
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 19
aggagctatg ttccttgggt tcttgggagc agcaggaagc actatgggct cagcgtcaat 60
ggcgctgacg gtacaggcca ggctattgtt gtctggtata gtgcaacagc agaacaattt 120
gctgagggct attgaggcgc aacagcatct gttgcaactc acagtctggg gcatcaagca 180
gctccaggca agaatcctgg ctgtggaaag atacctaaag gaccaacagc tcct 234
Claims (10)
1. An expression system for T7RNA polymerase and T7 promoter, comprising a Rev-RRE regulatory element in HIV-1 retrovirus.
2. The expression system of claim 1, wherein the T7RNA polymerase consists of SEQ ID No: 1, and coding the sequence represented by the symbol 1.
3. The expression system of claim 1 or 2, wherein the gene for T7RNA polymerase further comprises a nuclear localization sequence.
4. The expression system of claim 3, wherein the nuclear localization sequence is an SV40T-Antigen nuclear localization sequence, a Nucleoplasmin nuclear localization sequence, an EGL-13 nuclear localization sequence, a c-Myc nuclear localization sequence or a TUS-protein nuclear localization sequence.
5. A method for expressing a protein in a eukaryote using an expression system of T7RNA polymerase and T7 promoter, wherein said expression system comprises the Rev-RRE regulatory element in HIV-1 retrovirus.
6. The method of claim 5, wherein the method comprises:
1) constructing a vector expressing T7RNA polymerase and Rev, wherein the T7RNA polymerase consists of SEQ ID No: 1;
2) transferring a DNA fragment containing a T7 promoter, a T7 terminator, an IRES, an RRE and a target protein gene to the vector to construct a vector capable of expressing T7RNA polymerase, Rev and a target protein;
3) transfecting by using the vector constructed in the step 2) to finish slow virus packaging; and
4) infecting target eukaryotic cells with the lentivirus, obtaining a target transformant through resistance screening, and determining the expression system through verifying target protein.
7. The method of claim 5 or 6, wherein the T7RNA polymerase gene further comprises a nuclear localization sequence.
8. The method as claimed in claim 6 or 7, wherein in the step 1), a mammalian promoter is selected as a promoter for expressing T7RNA polymerase and Rev, and a eukaryotic polycistronic structure containing 2A or IRES is constructed to obtain a vector for simultaneously expressing T7RNA polymerase and Rev.
9. The method according to any one of claims 6 to 8, wherein the protein of interest expressed by the expression system is verified using a hygromycin resistance protein, Nanoluc luciferase or enhanced green fluorescent protein.
10. The method according to any one of claims 5 to 9, wherein the eukaryote is a mammal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210513779.1A CN114807228B (en) | 2020-04-27 | 2020-04-27 | Expression system of T7RNA polymerase and T7 promoter and method for expressing protein in eukaryote by using same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210513779.1A CN114807228B (en) | 2020-04-27 | 2020-04-27 | Expression system of T7RNA polymerase and T7 promoter and method for expressing protein in eukaryote by using same |
CN202010343730.7A CN111534533B (en) | 2020-04-27 | 2020-04-27 | Expression system of T7RNA polymerase and T7 promoter and method for expressing protein in eukaryote by using same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010343730.7A Division CN111534533B (en) | 2020-04-27 | 2020-04-27 | Expression system of T7RNA polymerase and T7 promoter and method for expressing protein in eukaryote by using same |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114807228A true CN114807228A (en) | 2022-07-29 |
CN114807228B CN114807228B (en) | 2023-12-15 |
Family
ID=71973291
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210513779.1A Active CN114807228B (en) | 2020-04-27 | 2020-04-27 | Expression system of T7RNA polymerase and T7 promoter and method for expressing protein in eukaryote by using same |
CN202010343730.7A Active CN111534533B (en) | 2020-04-27 | 2020-04-27 | Expression system of T7RNA polymerase and T7 promoter and method for expressing protein in eukaryote by using same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010343730.7A Active CN111534533B (en) | 2020-04-27 | 2020-04-27 | Expression system of T7RNA polymerase and T7 promoter and method for expressing protein in eukaryote by using same |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN114807228B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114181957B (en) * | 2021-12-03 | 2024-02-02 | 北京化工大学 | Stable T7 expression system based on virus capping enzyme and method for expressing protein in eukaryote |
CN114807210B (en) * | 2022-04-22 | 2024-02-02 | 北京化工大学 | T7 expression system based on cytoplasmic linear plasmid and method for expressing protein in yeast |
CN116926098A (en) * | 2023-07-31 | 2023-10-24 | 态创生物科技(广州)有限公司 | Directed evolution system and method for enhancing T7RNAP transcriptional activity on collagen/elastin |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106381310A (en) * | 2016-08-31 | 2017-02-08 | 武汉华美生物工程有限公司 | Method for expressing proteins in mammalian cells by T7 phage RNA polymerase and T7 promoter system |
CN110218734A (en) * | 2018-03-02 | 2019-09-10 | 清华大学 | A kind of expression component based on T7 expression system |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1182251A1 (en) * | 2000-08-11 | 2002-02-27 | Yissum Research Development Company of the Hebrew University of Jerusalem | Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB |
FR2872170B1 (en) * | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | NON-INTERACTIVE AND NON-REPLICATIVE LENTIVIRUS, PREPARATION AND USES |
CN102051378A (en) * | 2009-11-09 | 2011-05-11 | 中国医学科学院医药生物技术研究所 | Method for screening anti-HIV-1 (Human Immunodeficiency Virus) drugs with virus mRNA core transfer as target point |
-
2020
- 2020-04-27 CN CN202210513779.1A patent/CN114807228B/en active Active
- 2020-04-27 CN CN202010343730.7A patent/CN111534533B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106381310A (en) * | 2016-08-31 | 2017-02-08 | 武汉华美生物工程有限公司 | Method for expressing proteins in mammalian cells by T7 phage RNA polymerase and T7 promoter system |
CN110218734A (en) * | 2018-03-02 | 2019-09-10 | 清华大学 | A kind of expression component based on T7 expression system |
Non-Patent Citations (1)
Title |
---|
陈靓: "酿酒酵母中利用Rev-RRE元件跨核膜运输T7转录产物的初步研究", 中国优秀硕士学位论文全文数据库(电子期刊)基础科学辑, no. 01, pages 13 * |
Also Published As
Publication number | Publication date |
---|---|
CN111534533B (en) | 2022-04-19 |
CN114807228B (en) | 2023-12-15 |
CN111534533A (en) | 2020-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111534533B (en) | Expression system of T7RNA polymerase and T7 promoter and method for expressing protein in eukaryote by using same | |
CN106170552B (en) | Stable episomes based on non-integrating lentiviral vectors | |
Pacyniak et al. | Identification of a region within the cytoplasmic domain of the subtype B Vpu protein of human immunodeficiency virus type 1 (HIV-1) that is responsible for retention in the golgi complex and its absence in the Vpu protein from a subtype C HIV-1 | |
KR20160102024A (en) | A method of making adenovirus and corresponding plasmids | |
CN111154803B (en) | Preparation method and application of recombinant EBV gHgL immunogen | |
CN111500633A (en) | Recombinant canarypox virus construction method based on gene editing technology | |
CN108753827B (en) | A kind of targeting excretion body carries out carrier and its construction method and application that gene carries medicine | |
JP6871544B2 (en) | How to Produce a DNA Vector from a Molecular Component Containing a Sequence of Interest | |
CN113278635B (en) | Sequence combination for promoting cyclic RNA (ribonucleic acid) to form ring and application thereof | |
JP3844656B2 (en) | Methods for transformation of animal cells | |
US20180127837A1 (en) | Construction and application of one innovative expression vector for virus-like particles | |
JP7233545B2 (en) | Cell selection methods based on CRISPR/Cas-controlled incorporation of detectable tags into target proteins | |
CN112574992A (en) | Circular RNA over-expression cyclization vector DNA sequence and construction method and application thereof | |
CN111718956A (en) | Preparation method and application of chicken-derived TRIM25 gene recombinant fluorescent expression plasmid | |
CN107304432B (en) | Method for simultaneously expressing n proteins or protein subunits and special system thereof | |
CN107043785B (en) | Integrated lentivirus vector expression system | |
CN111304195B (en) | Annular RNA overexpression framework of low-background linear byproduct and construction method thereof | |
CN110305905B (en) | Mouse Tmem240 recombinant eukaryotic expression plasmid, lentivirus and construction method | |
CN107056899A (en) | A kind of cell membrane localization signal peptide and its encoding gene and application | |
CN112877332A (en) | Method for detecting activity of chicken RIPK2 promoter by using dual-luciferase reporter gene | |
CN111197060A (en) | Research method for targeted therapy of hematologic malignancy | |
CN114045305B (en) | Multi-swivel subsystem | |
CN108586586B (en) | HIV P10 protein interacting with hepatitis G virus E2 protein | |
CN110804626B (en) | Method for constructing high-efficiency expression vector by combining high CG segment and low CG promoter | |
CN113683689B (en) | Eukaryotic expression single-chain antibody of porcine-derived anti-porcine epidemic diarrhea virus N protein and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |